The p53 gene plays a crucial role in the control of cell growth and is frequently inactivated by mutations in cancer cells. Differently from most tumor types, p53 mutations in neuroblastoma (NB) are rare suggesting that p53 status is irrelevant in the pathogenesis of this tumor. The biological functions of p53 in NB, however, are inhibited by the accumulation of the protein in the cytoplasm. Moreover, after DNA damage, p53 translocates to the nucleus but its capacity to induce G1 cell-cycle arrest is attenuated.1,2,3
A considerable interest in NB research was recently raised by the discovery of p73, a p53 homologue located at 1p36.3, which transactivates several p53 target genes, induces apoptosis and inhibits cell proliferation. The contribution of p73 to tumor suppression however, is still unclear.4 p73 is a direct downstream effector of E2F-1 and is an essential component of the p53-independent apoptotic pathway. In developing sympathetic neurons of mice, p73 is predominantly expressed as a truncated anti-apoptotic isoform (ΔNp73), lacking the transactivation domain of the full length protein (TAp73). ΔNp73 antagonizes p53 and suppresses the transactivating activity of TAp73 by oligomerization and competition for DNA binding.5,6
We have demonstrated that the expression of the anti-apoptotic ΔNp73 variant in primary neuroblastoma is a strong, independent, predictor of unfavorable outcome.7 To gain further insights into the role of p73 in this tumor we investigated the control of ΔNp73 transcription in human neuroblastoma. Our results indicate that the expression of this p73 isoform is, at least in part, controlled by epigenetic changes in NB cell lines and tumor tissues.
Mouse ΔNp73 is transcribed from an internal promoter in the third intron of the p73 gene, upstream of an alternative exon 3 (exon 3′). We have cloned the human ΔNp73 cDNA and promoter by similarity with the mouse transcript. In Figure 1A, we report the genomic organization of the p73 locus. Nucleotide alignment between human and mouse ΔNp73 exon 3′ indicated that the two sequences share 78% homology.
Promoter prediction by neural network analysis detected a TATA box and a CAP signal immediately upstream from the putative human p73 exon 3′. The preliminary characterization of this region demonstrated that a 1400 bp fragment, that includes the entire exon 3′ cloned into a CAT reporter vector, indeed has promoter activities in the neuroblastoma cells lines SK-N-BE2(c) and LAN5 but not in U937, a myeloid cell line that constitutively does not express TA or ΔNp73 (Figure 1A).
RT–PCR analysis of a panel of cell lines showed that ΔNp73 is transcribed in 8 out of 11 NB cell lines tested but not in the myeloid HL60 or U937 cells. We were also unable to observe ΔNp73 mRNA expression in PBL from six healthy donors (data not shown). Sequencing of the RT–PCR products confirmed that the transcript was authentic ΔNp73 with a 1760 bp open reading frame coding for a protein with 92% homology to the mouse protein. Western blot analysis conducted with a pan-p73 monoclonal antibody on NB cell lines and on U937 cells (Figure 1B), detected a major band at 62 kDa only in the NB cells that express ΔNp73. This result indicates that ΔNp73α is the prevalent isoform present in these cell lines (Figure 1B and data not shown).
The 5′ end of ΔNp73, differently from that of the TA variant, does not contain a cluster of the consensus E2F binding sequence TT(C/G)(C/G)CG(C/G). The two regions, however share a similar structure. In both cases the first transcribed exon (exon 1 for TA and exon 3′ for ΔNp73) is part of a CpG island and a second CpG-rich region is located approximately 6 kb upstream from the putative transcription startpoint. Although the CpG-rich region at the ΔNp73 5′ end is considerably smaller than that of TAp73, it qualifies as a true island (length 336 bp; C+G content 64.2%; CpG/GpC=0.91, chi-square obs/exp=0.27) (Figure 1C).
In the mammalian genome, methylation of the cytosine residues within CpG dinucleotides plays an important role in the regulation of transcription and the importance of epigenetic modifications in the control of tumor cell growth is now well recognized. In leukemia and lymphomas, p73 silencing is associated with the aberrant methylation of the TAp73 promoter.8,9 In neuroblastoma, however, TAp73 transcription is subject to a different mode of regulation. In fact we did not observe a different level of methylation in primary NB expressing or not expressing TAp73.10 In an attempt to understand the mechanisms regulating ΔNp73 expression we have analyzed the methylation status of the ΔNp73 5′ region in neuroblastoma and control cell lines by Methylation Specific PCR (MSP). This technique relies upon the selective PCR amplification of methylated or unmethylated sequences after chemical conversion of the unmethylated C into T. The presence of an amplification band only with the primer set designed to bind to the methylated sequence indicated that the ΔNp73 5′ end is fully methylated in the ΔNp73-negative cell lines, U937, HL60 and ACN. Conversely neuroblastoma cell lines GI-ME-N, HTLA230 and SK-N-BE2(c), that express ΔNp73, displayed only partial methylation as witnessed by the presence of amplification bands with both sets of primers (Figure 1D). To determine if this epigenetic modification was present also in fresh normal and tumor cells we have analyzed the methylation status of ΔNp73 in T and B acute lymphocytic leukemia cells and in neuroblastoma tumor tissues and PBL from normal donors. As shown in Figure 1D, normal and leukemic lymphocytes display complete methylation of the ΔN 5′ region, a result consistent with the lack of ΔNp73 expression observed in these cells (7 and this report). On the contrary, in most primary NB expressing ΔNp73 this sequence is only partially methylated whereas it is fully methylated in two samples not expressing this isoform. These findings support the hypothesis that ΔNp73 expression is epigenetically regulated in NB.
Neuroblastoma is a childhood tumor that presents a high frequency of spontaneous regression likely due to the activation of apoptotic pathways. The p73 gene is a p53 homologue that can exert opposite functions: the full-length protein TAp73, can in fact induce apoptosis and neuronal differentiation4, while the truncated ΔN isoform is a dominant-negative inhibitor of programmed cell death. It thus appears that the p73 gene can functionally act as a tumor suppressor or as an anti-tumor suppressor.
Over the last few years it has become increasingly clear that epigenetic changes are essential for the normal development and that alterations of the pattern of DNA methylation are common in cancer cells. Hypermethylation of CpG residues within gene promoter regions can inhibit transcription and can participate in the inactivation of tumor-suppressor genes by acting, alternatively or synergistically to mutations or chromosomal deletions, in the multistep process of carcinogenesis. Another frequent epigenetic alteration of cancer cells is the decreased overall level of 5-methylcytosine. The implications of this modification in tumor progression are not yet completely understood although hypomethylation likely modifies the structural integrity of the chromosomes.11 The demethylation of specific loci can also reactivate gene expression and significantly alter the functionality of the cell as it was shown for the Bcl-2 gene in chronic lymphocytic leukemia.12 DNA methylation is a dynamic, reversible signal whose pattern depends largely on sequential methylation and demethylation events. Our results indicate that the expression of ΔNp73, another regulator of apoptosis, is associated with epigenetic changes. We propose that this mechanism finely modulates apoptotic signals in neuroblastoma tumors.
Note added in proof
After acceptance of this paper Grob et al.13 reported the functional characterization of the ΔNp73 promoter.
References
Vogan K et al. 1993 Cancer Res. 53: 5269–5273
Moll UM et al. 1995 Proc. Natl. Acad. Sci. USA. 92: 4407–4411
McKenzie PP et al. 1999 Clin. Cancer Res. 5: 4199–4207
Levrero M et al. 1999 J. Cell Sci. 113: 1161–1170
Yang A et al. 2000 Nature 404: 99–103
Pozniak CD et al. 2000 Science 289: 304–306
Casciano I et al. 2002 Cell Death Differ. 9: 246–251
Kawano S et al. 1999 Blood 94: 1113–1120
Corn PG et al. 1999 Cancer Res. 59: 3352–3356
Banelli B et al. 2000 Oncogene 19: 4553–4556
Wollfe AP et al. 1999 Proc. Natl. Acad. Sci. USA. 96: 5894–5896
Hanada et al. 1993 Blood 82: 1820–1828
Grob TJ et al. 2001 Cell Death Differ. 8: 1213–1223
Acknowledgements
We would like to express our gratitude to Lucio Luzzatto and Penny Lovat for encouragement and criticisms. B Banelli is a fellow of the Fondazione Italiana per la Ricerca sul Cancro (FIRC). M Croce is a fellow of the Associazione Italiana per la Lotta al Neuroblastoma (AILN). This work was supported by grants from the Associazione Italiana per la Lotta al Neuroblastoma (AILN), from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and from the Italian Health Ministry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Casciano, I., Banelli, B., Croce, M. et al. Role of methylation in the control of ΔNp73 expression in neuroblastoma. Cell Death Differ 9, 343–345 (2002). https://doi.org/10.1038/sj.cdd.4400992
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400992
This article is cited by
-
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression
Oncogene (2015)
-
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
Cell Death & Disease (2015)
-
Functions, divergence and clinical value of TAp73 isoforms in cancer
Cancer and Metastasis Reviews (2013)
-
Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer
Oncogene (2010)
-
Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors
Oncogene (2005)